AbbVie is entering the obesity treatment market with a $2.3bn licensing agreement to acquire global rights to GUB014295, a ...

Whether you have type 2 diabetes, obesity or just a few extra pounds that you’d like some help shedding, chances are you’re ...

AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...

The FDA has declared that the shortage of popular weight-loss drugs, including Ozempic and Wegovy, is officially over.

We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts. In this article, we are going ...

Semaglutide may help reduce alcohol cravings and intake, according to a clinical trial. Participants receiving the drug drank ...

Hims & Hers saw a massive YTD surge, but FDA news led to a pullback. Find out why HIMS stock is still undervalued and why ...

Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their ...

Although the telemedicine company displayed blistering growth and issued robust guidance, shares of Hims & Hers (NYSE: HIMS) ...

Ozempic and its ilk may do a lot of things, but raising the risk of suicide doesn’t appear to be one of them. Research out ...

Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.